Andy Chen
Stock Analyst at Wolfe Research
(2.26)
# 2,627
Out of 4,876 analysts
38
Total ratings
46.15%
Success rate
-0.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $45.03 | +8.82% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $17.34 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $29.80 | +84.56% | 1 | Jun 17, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Peer Perform | n/a | $128.21 | - | 1 | Jun 3, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $48.25 | +26.42% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $9.78 | +114.72% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $22.77 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $30.50 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $9.81 | - | 1 | Feb 4, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Outperform | $20 | $11.31 | +76.83% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $23.14 | +111.75% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $9.95 | +91.00% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $16.06 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $561.14 | +24.21% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $321.27 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $69.20 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $20.68 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $44.09 | +47.43% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.89 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $303.67 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $14.59 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $8.99 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $39.66 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $47.25 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.42 | +48.93% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $445.75 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $100.80 | -58.33% | 1 | Feb 15, 2024 |
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $45.03
Upside: +8.82%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $17.34
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $29.80
Upside: +84.56%
Blueprint Medicines
Jun 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $128.21
Upside: -
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $48.25
Upside: +26.42%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $9.78
Upside: +114.72%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $22.77
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $30.50
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $9.81
Upside: -
Oruka Therapeutics
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $11.31
Upside: +76.83%
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $23.14
Upside: +111.75%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $9.95
Upside: +91.00%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $16.06
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $561.14
Upside: +24.21%
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $321.27
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $69.20
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $20.68
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $44.09
Upside: +47.43%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $55.89
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $303.67
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $14.59
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $8.99
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $39.66
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $47.25
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.42
Upside: +48.93%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $445.75
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $100.80
Upside: -58.33%